Matsumoto, Japan

Jun Amano


 


Average Co-Inventor Count = 5.4

ph-index = 3

Forward Citations = 37(Granted Patents)


Location History:

  • Matsumoto, JP (2010 - 2014)
  • Nagano, JP (2014)

Company Filing History:


Years Active: 2010-2014

Loading Chart...
Loading Chart...
Loading Chart...
7 patents (USPTO):Explore Patents

Title: Jun Amano: Innovator in Gene Delivery Systems

Introduction

Jun Amano is a prominent inventor based in Matsumoto, Japan. He has made significant contributions to the field of gene delivery systems, holding a total of 7 patents. His work focuses on developing methods that enhance the efficiency of gene transport and therapeutic applications.

Latest Patents

Amano's latest patents include a method of constructing a gene transport support. This invention aims to provide an efficient method for creating a gene delivery carrier that exhibits favorable activity and expression efficiency of proteins introduced through transformation. Additionally, he has developed a pharmaceutical composition that includes a gene delivery carrier and a therapeutic agent for solid tumors, utilizing resistant bacteria. Another notable patent involves a method for producing a 5-fluorouracil-resistant microorganism that can grow in anaerobic tumor tissues and express cytosine deaminase, which is crucial for antitumor activity.

Career Highlights

Throughout his career, Jun Amano has worked with various companies, including Anaeropharma Science, Inc. and Kringle Pharma Inc. His innovative approaches have positioned him as a key figure in the biotechnology sector, particularly in the development of cancer therapies.

Collaborations

Amano has collaborated with notable individuals in his field, including Minoru Fujimori and Shun'ichiro Taniguchi. These partnerships have furthered his research and contributed to advancements in gene delivery technologies.

Conclusion

Jun Amano's contributions to gene delivery systems and his innovative patents highlight his role as a leading inventor in biotechnology. His work continues to pave the way for new therapeutic strategies in cancer treatment.

This text is generated by artificial intelligence and may not be accurate.
Please report any incorrect information to support@idiyas.com
Loading…